Market Research Logo

Global HDAC (histone deacetylase) Inhibitors Market 2019-2023

Global HDAC (histone deacetylase) Inhibitors Market 2019-2023

About this market

The development of novel drug delivery systems and combination therapies will drive the HDAC inhibitors market growth during the forecast period. Chemotherapeutic drugs are increasingly being administered orally or intravenously for treating different tumors. However, there are instances that these active pharmaceutical ingredients often do not reach the targeted site in appropriate quantities, eventually, lowering the performance of the drugs. As a result, with the rising shift of research and prescription toward combination therapies using HDAC inhibitors, the market is expected to witness considerable growth during the forthcoming years. Technavio’s analysts have predicted that the HDAC (histone deacetylase) inhibitors market will register a CAGR of nearly 7% by 2023.

Market Overview

High prevalence of oncology indications

One of the growth drivers of the global HDAC (histone deacetylase) inhibitors market is the high prevalence of oncology indications. The high growth in various types of cancers and neurologic conditions, coupled with high unmet need in the treatment landscape of these diseases will drive the growth of the market.

High costs associated with treatment

One of the challenges in the growth of the global HDAC (histone deacetylase) inhibitors market is the high costs associated with treatment. The high treatment costs act as a barrier for drug adoption, which reduces the patient base and poses a challenge to market growth.

For the detailed list of factors that will drive and challenge the growth of the HDAC (histone deacetylase) inhibitors market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Companies are focusing on research on several other types of cancers using HDAC inhibitors due to their high target affinity and specificity. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.


Press Release

Technavio Announces the Publication of its Research Report – Global HDAC (Histone Deacetylase) Inhibitors Market 2019-2023

Technavio recognizes the following companies as the key players in the global HDAC (histone deacetylase) inhibitors market: CELGENE CORPORATION, Merck & Co., Inc., Novartis AG, Shenzhen Chipscreen Biosciences Co., Ltd., and Spectrum Pharmaceuticals, Inc.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the increasing awareness about cancer.”

According to the report, one of the major drivers for this market is the development of novel drug delivery systems and combination therapies.

Further, the report states that one of the major factors hindering the growth of this market is the high costs associated with treatment.

Companies Mentioned

CELGENE CORPORATION
Merck & Co., Inc.
Novartis AG
Shenzhen Chipscreen Biosciences Co., Ltd.
Spectrum Pharmaceuticals, Inc.

  • Executive summary
  • Scope of the report
    • Preface
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global pharmaceuticals market
      • Table Segments of global pharmaceuticals market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Customer landscape
    • Table Customer landscape
  • Market segmentation by RoA
    • Table RoA - Market share 2018-2023 (%)
    • Comparison by RoA
      • Table Comparison by RoA
    • Oral HDAC inhibitors - Market size and forecast 2018-2023
      • Table Oral HDAC inhibitors - Market size and forecast 2018-2023 ($ millions)
      • Table Oral HDAC inhibitors: Pipeline overview
      • Table Oral HDAC inhibitors - Year-over-year growth 2019-2023 (%)
    • Parenteral HDAC inhibitors - Market size and forecast 2018- 2023
      • Table Parenteral HDAC inhibitors - Market size and forecast 2018-2023 ($ millions)
      • Table Parenteral HDAC inhibitors - Year-over-year growth 2019-2023 (%)
    • Market opportunity by RoA
      • Table Market opportunity by RoA
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in North America
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Europe
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Asia
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in ROW
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Prevalence of top 5 cancers newly reported in US 2015
      • Table Pipeline of combination therapies - Syndax
    • Market challenges
      • Table Treatment costs of HDAC inhibitors
      • Table Alternative treatment options for oncology conditions
      • Table Side effects of HDAC
      • Table Impact of drivers and challenges
  • Market trends
    • Table Some strategic alliances in global HDAC inhibitors market
    • Table drugs with respect to their cancer indications and expanded indications
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive scenario
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • CELGENE CORPORATION
      • Table CELGENE CORPORATION - Vendor overview
      • Table CELGENE CORPORATION - Business segments
      • Table CELGENE CORPORATION - Organizational developments
      • Table CELGENE CORPORATION - Geographic focus
      • Table CELGENE CORPORATION - Key offerings
      • Table CELGENE CORPORATION - Key customers
    • Merck & Co., Inc.
      • Table Merck & Co., Inc. - Vendor overview
      • Table Merck & Co., Inc. - Business segments
      • Table Merck & Co., Inc. - Organizational developments
      • Table Merck & Co., Inc. - Geographic focus
      • Table Merck & Co., Inc. - Segment focus
      • Table Merck & Co., Inc. - Key offerings
      • Table Merck & Co., Inc. - Key customers
    • Novartis AG
      • Table Novartis AG - Vendor overview
      • Table Novartis AG - Business segments
      • Table Novartis AG - Organizational developments
      • Table Novartis AG - Geographic focus
      • Table Novartis AG - Segment focus
      • Table Novartis AG - Key offerings
      • Table Novartis AG - Key customers
    • Shenzhen Chipscreen Biosciences Co., Ltd.
      • Table Shenzhen Chipscreen Biosciences Co., Ltd. - Vendor overview
      • Table Shenzhen Chipscreen Biosciences Co., Ltd. - Organizational developments
      • Table Shenzhen Chipscreen Biosciences Co., Ltd. - Key offerings
      • Table Shenzhen Chipscreen Biosciences Co., Ltd. - Key customers
    • Spectrum Pharmaceuticals, Inc.
      • Table Spectrum Pharmaceuticals, Inc. - Vendor overview
      • Table Spectrum Pharmaceuticals, Inc. - Business segments
      • Table Spectrum Pharmaceuticals, Inc. - Organizational developments
      • Table Spectrum Pharmaceuticals, Inc. - Geographic focus
      • Table Spectrum Pharmaceuticals, Inc. - Key offerings
      • Table Spectrum Pharmaceuticals, Inc. - Key customers
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report